170 related articles for article (PubMed ID: 23888962)
21. Panobinostat Enhances Growth Suppressive Effects of Progestin on Endometrial Carcinoma by Increasing Progesterone Receptor and Mitogen-Inducible Gene-6.
Ando H; Miyamoto T; Kashima H; Higuchi S; Ida K; Mvunta DH; Shiozawa T
Horm Cancer; 2017 Aug; 8(4):257-267. PubMed ID: 28516379
[TBL] [Abstract][Full Text] [Related]
22. Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region.
Liang Y; Zeng J; Jelicks L; Ma S; Liu J; Mei J; Perez-Soler R; Zou Y
Curr Cancer Drug Targets; 2017; 17(2):169-176. PubMed ID: 27029827
[TBL] [Abstract][Full Text] [Related]
23. MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells.
Imesch P; Dedes KJ; Furlato M; Fink D; Fedier A
Int J Oncol; 2009 Sep; 35(3):631-40. PubMed ID: 19639184
[TBL] [Abstract][Full Text] [Related]
24. DNA methylation and histone modifications regulate SOX11 expression in lymphoid and solid cancer cells.
Nordström L; Andersson E; Kuci V; Gustavsson E; Holm K; Ringnér M; Guldberg P; Ek S
BMC Cancer; 2015 Apr; 15():273. PubMed ID: 25880212
[TBL] [Abstract][Full Text] [Related]
25. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
Sakajiri S; Kumagai T; Kawamata N; Saitoh T; Said JW; Koeffler HP
Exp Hematol; 2005 Jan; 33(1):53-61. PubMed ID: 15661398
[TBL] [Abstract][Full Text] [Related]
27. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
Duvic M; Dimopoulos M
Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
[TBL] [Abstract][Full Text] [Related]
28. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy.
Valdez BC; Li Y; Murray D; Brammer JE; Liu Y; Hosing C; Nieto Y; Champlin RE; Andersson BS
Oncotarget; 2016 Sep; 7(39):63829-63838. PubMed ID: 27564097
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience.
Bezecny P
Med Oncol; 2014 Jun; 31(6):985. PubMed ID: 24838514
[TBL] [Abstract][Full Text] [Related]
30. The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway.
Sarfstein R; Bruchim I; Fishman A; Werner H
PLoS One; 2011; 6(9):e24468. PubMed ID: 21931726
[TBL] [Abstract][Full Text] [Related]
31. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
Cang S; Ma Y; Liu D
J Hematol Oncol; 2009 Jun; 2():22. PubMed ID: 19486511
[TBL] [Abstract][Full Text] [Related]
32. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
[TBL] [Abstract][Full Text] [Related]
33. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase inhibitors in programmed cell death and cancer therapy.
Marks PA; Jiang X
Cell Cycle; 2005 Apr; 4(4):549-51. PubMed ID: 15738652
[TBL] [Abstract][Full Text] [Related]
35. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
Richon VM
Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
[TBL] [Abstract][Full Text] [Related]
36. Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer.
Oh S; Ko JY; Oh C; Yoo KH
Adv Exp Med Biol; 2017; 1026():287-313. PubMed ID: 29282690
[TBL] [Abstract][Full Text] [Related]
37. HDAC inhibitor Vorinostat and BET inhibitor Plx51107 epigenetic agents' combined treatments exert a therapeutic approach upon acute myeloid leukemia cell model.
Alcitepe İ; Salcin H; Karatekin İ; Kaymaz BT
Med Oncol; 2022 Oct; 39(12):257. PubMed ID: 36224430
[TBL] [Abstract][Full Text] [Related]
38. HDAC inhibitors: clinical update and mechanism-based potential.
Glaser KB
Biochem Pharmacol; 2007 Sep; 74(5):659-71. PubMed ID: 17498667
[TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
Kumagai T; Wakimoto N; Yin D; Gery S; Kawamata N; Takai N; Komatsu N; Chumakov A; Imai Y; Koeffler HP
Int J Cancer; 2007 Aug; 121(3):656-65. PubMed ID: 17417771
[TBL] [Abstract][Full Text] [Related]
40. Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis.
Huang YC; Huang FI; Mehndiratta S; Lai SC; Liou JP; Yang CR
Oncotarget; 2015 Jul; 6(21):18590-601. PubMed ID: 26087180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
